ClinicalTrials.gg
CompletedNCT03448081Updated Feb 8, 2019

Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene

A Phase 2 interventional study of SNA-120 and Placebo in Pruritus and Psoriasis, sponsored by Sienna Biopharmaceuticals. Completed at 20 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-08.

Sponsored by Sienna Biopharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2018, 7 years 11 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Feb 2019.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 163 studies in Pruritus with a site in United States — 24 open to participants now, 28 under way, 8 of them phase 3. Pruritus · United States.

Enrollment
75th of 153
73 · median 70
Started
2018
with 12 others
Phase 2
60 of 163
6 open now
Registered
70th of 163
by date

Among the 163 studies in Pruritus with a site in United States, this one is the 75th largest by enrollment of the 153 interventional ones that give a count, is one of 13 that started in 2018, is one of 60 in phase 2, and was the 70th registered.

Pruritus

491 studies on the registry are indexed under Pruritus; 94 are open to participants now.

Browse Pruritus studies →

Open to participants now

24 of the 163 studies in Pruritus with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies in Pruritus with a site in United States, or all of them as a file.
02

Study summary

A Phase 2 study evaluating safety, tolerability, and efficacy of SNA-120 ointment when administered topically with calcipotriene ointment for the treatment of pruritus and psoriasis.

Read the detailed description

All subjects are required to meet eligibility requirements and undergo a calcipotriene run-in period (Part A) prior to qualifying and randomizing into the study to receive either SNA-120 or Placebo ointment in combination with calcipotriene ointment (Part B). Combination therapy (SNA-120 ointment + calcipotriene ointment or Placebo ointment + calcipotriene ointment) is to continue over an 8 week period to evaluate safety, tolerability and the efficacy of treatment on both persistent pruritus and the visible signs and symptoms of psoriasis.

03

Conditions studied

  • Pruritus
  • Psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Stable psoriasis for at least 6 months prior to screening
  • Chronic pruritus of the psoriasis plaques at least 6 weeks prior to screening
  • At least moderate baseline overall itch associated with psoriatic plaques
  • Willing and able to undergo a 4-week run-in with calcipotriene ointment dosing and remain on this stable regimen throughout the study
  • Mild or moderate psoriasis at screening and baseline
  • Subject's plaques are amenable to treatment with a topical medication
  • Willing and able to discontinue all other topical products to treat psoriasis and/or itch, including topical
  • Willing and able to avoid prolonged exposure of the designated treatment plaques to ultraviolet (UV) radiation (natural and artificial) for the duration of the study
  • Women of must have a negative pregnancy test and must agree to use highly effective methods of during the study
  • Men who engage in sexual activity that can result in fathering children must agree to use highly effective forms of contraception during the study

Exclusion criteria

Exclusion Criteria:

  • Underlying conditions other than psoriasis that, in the opinion of the investigator, currently cause or influence pruritus of the overall skin
  • Current or past history of hypercalcemia, Vitamin D toxicity, severe renal insufficiency, or severe hepatic disorders
  • Thyroid abnormalities that, in the opinion of the investigator, are and may affect assessments
  • Current diagnosis of guttate, erythrodermic, exfoliative, or pustular psoriasis
  • Subjects with a clinical diagnosis of bacterial infection of the skin
  • Subjects who have previously failed treatment with or failed to tolerate treatment with calcipotriene
  • Known to SNA-120 (pegcantratinib), calcipotriene, the study treatment , and /or polyethylene glycol (PEG), or a history of drug or other allergy that, in the opinion of the investigator, contraindicates participation
  • Currently enrolled in an drug or device study or has used an investigational drug or an investigational device treatment within 30 days or 5 half-lives of investigational drug (whichever is longer) of baseline
  • Women who are pregnant or lactating, or are planning to become pregnant during the study
  • Subjects previously participating in any SNA-120 (and/or CT327 or pegcantratinib) clinical studies
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
73 participants (actual)

Study arms

  • Active comparator
    SNA-120 + Calcipotriene

    Drug: SNA-120 · Drug: Calcipotriene

  • Placebo comparator
    Placebo + Calcipotriene

    Drug: Placebo · Drug: Calcipotriene

Interventions

  • SNA-120 (0.5%) active ointment

  • DrugPlacebo

    Vehicle Ointment

  • Calcipotriene ointment (0.005%)

06

What researchers measure

Primary outcomes

  1. Change in Itch Numeric Rating Scale scores (I-NRS) from baseline

    11-point NRS scale used to assess pruritus severity, ranging from 0 (no itching at all) to 10 (worst possible itching)

    Time frame: week 8

Secondary outcomes

  1. Change in Investigator Global Assessment (IGA) from baseline

    5-point scale used to assess the overall severity of psoriasis by evaluting induration, erythema and desquamation (0=clear to 4=severe)

    Time frame: week 8

  2. Change in Psoriasis Area Severity Index (PASI) from baseline

    A quantitative rating score for measuring the severity of psoriatic lesions based on area coverage and plaque appearance (0 = no disease to 72 = maximum disease)

    Time frame: week 8

Other outcomes

  1. Safety measured by frequency of Adverse Events

    Frequency of all Adverse Events (AEs), including local site reactions that occur during the trial from baseline through week 10

    Time frame: week 10

  2. Safety measured by severity of Adverse Events

    Severity of all Adverse Events (AEs), including local site reactions that occur during the trial from baseline through week 10

    Time frame: week 10

  3. Safety measured by change in clinical lab results from baseline

    biochemistry lab assessments

    Time frame: week 10

  4. Safety measured by change in clinical lab results from baseline

    Clinical laboratory assessments include urinalysis (pH, glucose, protein)

    Time frame: week 10

  5. Safety measured by change in clinical lab results from baseline

    hematology lab assessments

    Time frame: week 10

  6. Safety measured by change from baseline in blood pressure

    Systolic/diastolic blood pressure (BP in mmHg) - measured every full clinic visit, from baseline through week 10

    Time frame: week 10

  7. Safety measured by change from baseline in pulse

    Measured in beats per minute (bpm) - measured every full clinic visit, from baseline through week 10

    Time frame: week 10

  8. Safety measured by number of abnormal physical examinations from baseline

    Time frame: week 8

  9. Safety measured by PR/PQ intervals measured by 12-lead ECG

    Safety measured by PR/PQ intervals measured by 12-lead ECG at screening

    Time frame: week -4

  10. Safety measured by PR/PQ intervals measured by 12-lead ECG

    Safety measured by PR/PQ intervals measured by 12-lead ECG at baseline

    Time frame: week 0

  11. Safety measured by PR/PQ intervals measured by 12-lead ECG

    Safety measured by PR/PQ intervals measured by 12-lead ECG at week 4

    Time frame: week 4

  12. Safety measured by PR/PQ intervals measured by 12-lead ECG

    Safety measured by PR/PQ intervals measured by 12-lead ECG at week 8

    Time frame: week 8

  13. Safety measured by QRS duration measured by 12-lead ECG

    Safety measured by QRS duration measured by 12-lead ECG at screening

    Time frame: week -4

  14. Safety measured by QRS duration measured by 12-lead ECG

    Safety measured by QRS duration measured by 12-lead ECG at baseline

    Time frame: week 0

  15. Safety measured by QRS duration measured by 12-lead ECG

    Safety measured by QRS duration measured by 12-lead ECG at week 4

    Time frame: week 4

  16. Safety measured by QRS duration measured by 12-lead ECG

    Safety measured by QRS duration measured by 12-lead ECG at week 8

    Time frame: week 8

  17. Safety measured by QT intervals measured by 12-lead ECG

    Safety measured by QT intervals measured by 12-lead ECG at screening

    Time frame: week -4

  18. Safety measured by QT intervals measured by 12-lead ECG

    Safety measured by QT intervals measured by 12-lead ECG at baseline

    Time frame: week 0

  19. Safety measured by QT intervals measured by 12-lead ECG

    Safety measured by QT intervals measured by 12-lead ECG at week 4

    Time frame: week 4

  20. Safety measured by QT intervals measured by 12-lead ECG

    Safety measured by QT intervals measured by 12-lead ECG at week 8

    Time frame: week 8

07

Study locations

20 sites
  • Sienna 018
    Anniston, Alabama 36207, United States
  • Sienna 009
    Mobile, Alabama 36608, United States
  • Sienna 019
    Fountain Valley, California 92708, United States
  • Sienna 007
    Los Angeles, California 90045, United States
  • Site 016
    Sherman Oaks, California 91403, United States
  • Site 013
    Coral Gables, Florida 33143, United States
  • Site 015
    Sanford, Florida 32771, United States
  • Site 012
    Indianapolis, Indiana 46256, United States
  • Sienna 011
    Warren, Michigan 48088, United States
  • Sienna 005
    Berlin, New Jersey 08009, United States
  • Sienna 020
    Rochester, New York 14623, United States
  • Site 014
    Raleigh, North Carolina 27612, United States
  • Sienna 002
    Oklahoma City, Oklahoma 73118, United States
  • Sienna 017
    Austin, Texas 78745, United States
  • Sienna 010
    Houston, Texas 77004, United States
  • Sienna 021
    Pflugerville, Texas 78660, United States
  • Sienna 001
    San Antonio, Texas 78213, United States
  • Sienna 006
    Surrey, British Columbia V3R 6A7, Canada
  • Sienna 008
    Peterborough, Ontario K9J 5K2, Canada
  • Sienna 003
    Montreal, Quebec H2K 4L5, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Nov 2018, 9 months.

Of 37 industry-sponsored phase 2 interventional studies under Pruritus, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 21. This study's 9 months is below that.

Counting every sponsor, half of 52 studies reached it within 16 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2018
First posted
Feb 27, 2018
StartActual
Feb 12, 2018
Primary completionActual
Nov 21, 2018
CompletionActual
Dec 10, 2018
Results delay requested
Feb 4, 2019
Last update
Feb 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03448081
Lead sponsor
Sienna Biopharmaceuticals
Responsible party
Sponsor
First posted
Feb 27, 2018
Start date
Feb 12, 2018
Primary completion
Nov 21, 2018
Completion
Dec 10, 2018
Last update
Feb 8, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegcantratinib

Start the discussion